{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:24:15Z","timestamp":1792427055525,"version":"4.5.0"},"posted":{"date-parts":[[2023,6,27]]},"group-title":"In Review","reference-count":50,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,6,16]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Background<\/bold> Alzheimer\u2019s disease (AD) is a complex heterogenous neurodegenerative disorder, characterized by multiple pathophysiologies, including disruptions in brain metabolism. Defining markers for patient stratification across these pathophysiologies is an important step towards personalized treatment of AD. Efficient brain glucose metabolism is essential to sustain neuronal activity, but hypometabolism is consistently observed in AD. The molecular changes underlying these observations remain unclear. Recent studies have indicated dysregulation of several glycolysis markers in AD cerebrospinal fluid and tissue.<bold>Methods<\/bold> In this study, unbiased mass spectrometry was used to perform a deep proteomic survey of cerebrospinal fluid (CSF) from a large-scale clinically complex cohort to uncover changes related to impaired glucose metabolism.<bold>Results<\/bold> Two glycolytic enzymes, Pyruvate kinase (PKM) and Aldolase A (ALDOA) were found to be specifically upregulated in AD CSF compared to other non-AD groups. Presence of full-length protein of these enzymes in CSF was confirmed through immunoblotting. Levels of tryptic peptides of these enzymes correlated significantly with CSF glucose and CSF lactate in matching CSF samples.<bold>Conclusions<\/bold> The results presented here indicate a general dysregulation of glucose metabolism in the brain in AD. We highlight two markers ALDOA and PKM that may act as potential functionally-relevant biomarkers of glucose metabolism dysregulation in AD.<\/p>","DOI":"10.21203\/rs.3.rs-3073597\/v1","type":"posted-content","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T19:23:26Z","timestamp":1687893806000},"source":"Crossref","is-referenced-by-count":2,"title":["Mass Spectrometry in Cerebrospinal Fluid Uncovers Association of Glycolysis Biomarkers with Alzheimer\u2019s Disease in a Large Clinical Sample"],"prefix":"10.21203","author":[{"given":"Matthijs B.","family":"de Geus","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Leslie","sequence":"additional","affiliation":[{"name":"Yale School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TuKiet","family":"Lam","sequence":"additional","affiliation":[{"name":"Yale School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Yale School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Kivisakk","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus C.","family":"Nairn","sequence":"additional","affiliation":[{"name":"Yale School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky C.","family":"Carlyle","sequence":"additional","affiliation":[{"name":"Kavli Institute for Nanoscience Discovery"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8761","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2022 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s & Dementia. 2022;18(4):700\u2013789. doi:10.1002\/ALZ.12638","DOI":"10.1002\/alz.12638"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146\/ANNUREV-BIOCHEM-061516-045115","author":"Chiti F","year":"2017","unstructured":"Chiti F, Dobson CM. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. https:\/\/doi-org.ezp-prod1.hul.harvard.edu\/101146\/annurev-biochem-061516-045115. 2017;86:27\u201368. doi:10.1146\/ANNUREV-BIOCHEM-061516-045115"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/NRN3880","author":"Heppner FL","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nature Reviews Neuroscience 2015 16:6. 2015;16(6):358\u2013372. doi:10.1038\/NRN3880"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/J.DADM.2017.01.005","article-title":"Pathophysiologic relationship between Alzheimer\u2019s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis","volume":"7","author":"Santos CY","year":"2017","unstructured":"Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer\u2019s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2017;7(1):69\u201387. doi:10.1016\/J.DADM.2017.01.005","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"5","key":"ref5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/JOIM.12534","article-title":"Insulin signalling in Alzheimer\u2032s disease and diabetes: from epidemiology to molecular links","volume":"280","author":"Ribe EM","year":"2016","unstructured":"Ribe EM, Lovestone S. Insulin signalling in Alzheimer\u2032s disease and diabetes: from epidemiology to molecular links. J Intern Med. 2016;280(5):430\u2013442. doi:10.1111\/JOIM.12534","journal-title":"J Intern Med"},{"issue":"4","key":"ref6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/J.JALZ.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack CR","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2018;14(4):535\u2013562. doi:10.1016\/J.JALZ.2018.02.018","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/S12276-019-0250-2","author":"Lee JC","year":"2019","unstructured":"Lee JC, Kim SJ, Hong S, Kim YS. Diagnosis of Alzheimer\u2019s disease utilizing amyloid and tau as fluid biomarkers. Experimental & Molecular Medicine 2019 51:5. 2019;51(5):1\u201310. doi:10.1038\/S12276-019-0250-2"},{"issue":"3","key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2016-012546","article-title":"Association of comorbidity and health service usage among patients with dementia in the UK: a population-based study","volume":"7","author":"Browne J","year":"2017","unstructured":"Browne J, Edwards DA, Rhodes KM, Brimicombe DJ, Payne RA. Association of comorbidity and health service usage among patients with dementia in the UK: a population-based study. BMJ Open. 2017;7(3). doi:10.1136\/BMJOPEN-2016-012546","journal-title":"BMJ Open"},{"issue":"Suppl 1","key":"ref9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/S40120-017-0073-9","article-title":"A Review of Fluid Biomarkers for Alzheimer\u2019s Disease: Moving from CSF to Blood","volume":"6","author":"Blennow K","year":"2017","unstructured":"Blennow K. A Review of Fluid Biomarkers for Alzheimer\u2019s Disease: Moving from CSF to Blood. Neurol Ther. 2017;6(Suppl 1):15. doi:10.1007\/S40120-017-0073-9","journal-title":"Neurol Ther"},{"issue":"9","key":"ref10","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1212\/01.WNL.0000269790.05105.16","article-title":"What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?","volume":"69","author":"Jagust W","year":"2007","unstructured":"Jagust W, Reed B, Mungas D, Ellis W, DeCarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69(9):871\u2013877. doi:10.1212\/01.WNL.0000269790.05105.16","journal-title":"Neurology"},{"issue":"1","key":"ref11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack CR","year":"2010","unstructured":"Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet neurology. 2010;9(1):119. doi:10.1016\/S1474-4422(09)70299-6","journal-title":"Lancet neurology"},{"issue":"10","key":"ref12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tins.2013.07.001","article-title":"Sugar for the brain: the role of glucose in physiological and pathological brain function","volume":"36","author":"Mergenthaler P","year":"2013","unstructured":"Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 2013;36(10):587\u2013597. doi:10.1016\/j.tins.2013.07.001","journal-title":"Trends Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/S13195-022-00996-8","author":"Gonz\u00e1lez A","year":"2022","unstructured":"Gonz\u00e1lez A, Calf\u00edo C, Churruca M, Maccioni RB. Glucose metabolism and AD: evidence for a potential diabetes type 3. Alzheimer\u2019s Research & Therapy 2022 14:1. 2022;14(1):1\u201311. doi:10.1186\/S13195-022-00996-8"},{"issue":"FEB","key":"ref14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/FNINS.2017.00043\/BIBTEX","article-title":"Lactate shuttles in neuroenergetics-homeostasis, allostasis and beyond","volume":"11","author":"Mason S","year":"2017","unstructured":"Mason S. Lactate shuttles in neuroenergetics-homeostasis, allostasis and beyond. Front Neurosci. 2017;11(FEB):43. doi:10.3389\/FNINS.2017.00043\/BIBTEX","journal-title":"Front Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/S41574-018-0048-7","author":"Biessels GJ","year":"2018","unstructured":"Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nature Reviews Endocrinology 2018 14:10. 2018;14(10):591\u2013604. doi:10.1038\/S41574-018-0048-7"},{"issue":"3","key":"ref16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/NRNEUROL.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold SE","year":"2018","unstructured":"Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14(3):168\u2013181. doi:10.1038\/NRNEUROL.2017.185","journal-title":"Nat Rev Neurol"},{"issue":"17","key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS23179540","article-title":"Dysfunctional Glucose Metabolism in Alzheimer\u2019s Disease Onset and Potential Pharmacological Interventions","volume":"23","author":"Kumar V","year":"2022","unstructured":"Kumar V, Kim SH, Bishayee K. Dysfunctional Glucose Metabolism in Alzheimer\u2019s Disease Onset and Potential Pharmacological Interventions. Int J Mol Sci. 2022;23(17). doi:10.3390\/IJMS23179540","journal-title":"Int J Mol Sci"},{"issue":"43","key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/SCIADV.AAZ9360","article-title":"Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease","volume":"6","author":"Higginbotham L","year":"2020","unstructured":"Higginbotham L, Ping L, Dammer EB, et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease. Sci Adv. 2020;6(43). doi:10.1126\/SCIADV.AAZ9360","journal-title":"Sci Adv"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-020-0815-6","author":"Johnson ECB","year":"2020","unstructured":"Johnson ECB, Dammer EB, Duong DM, et al. Large-scale proteomic analysis of Alzheimer\u2019s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine 2020 26:5. 2020;26(5):769\u2013780. doi:10.1038\/S41591-020-0815-6"},{"issue":"4","key":"ref20","doi-asserted-by":"publisher","first-page":"e1800105","DOI":"10.1002\/prca.201800105","article-title":"Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer\u2019s Disease","volume":"13","author":"Sathe G","year":"2019","unstructured":"Sathe G, Na CH, Renuse S, et al. Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer\u2019s Disease. Proteomics Clin Appl. 2019;13(4):e1800105. doi:10.1002\/prca.201800105","journal-title":"Proteomics Clin Appl"},{"issue":"1","key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/S12014-020-09285-8","article-title":"Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer\u2019s disease","volume":"17","author":"Zhou M","year":"2020","unstructured":"Zhou M, Haque RU, Dammer EB, et al. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer\u2019s disease. Clin Proteomics. 2020;17(1). doi:10.1186\/S12014-020-09285-8","journal-title":"Clin Proteomics"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/S41593-021-00999-Y","author":"Johnson ECB","year":"2022","unstructured":"Johnson ECB, Carter EK, Dammer EB, et al. Large-scale deep multi-layer analysis of Alzheimer\u2019s disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nature Neuroscience 2022 25:2. 2022;25(2):213\u2013225. doi:10.1038\/S41593-021-00999-Y"},{"issue":"1","key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13195-018-0397-4\/FIGURES\/4","article-title":"Alzheimer disease pathology and the cerebrospinal fluid proteome","volume":"10","author":"Dayon L","year":"2018","unstructured":"Dayon L, N\u00fa\u00f1ez Galindo A, Wojcik J, et al. Alzheimer disease pathology and the cerebrospinal fluid proteome. Alzheimers Res Ther. 2018;10(1):1\u201312. doi:10.1186\/S13195-018-0397-4\/FIGURES\/4","journal-title":"Alzheimers Res Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/J.NEUROBIOLAGING.2021.04.012","article-title":"Synaptic proteins associated with cognitive performance and neuropathology in older humans revealed by multiplexed fractionated proteomics","volume":"105","author":"Carlyle BC","year":"2021","unstructured":"Carlyle BC, Kandigian SE, Kreuzer J, et al. Synaptic proteins associated with cognitive performance and neuropathology in older humans revealed by multiplexed fractionated proteomics. Neurobiol Aging. 2021;105:99\u2013114. doi:10.1016\/J.NEUROBIOLAGING.2021.04.012","journal-title":"Neurobiol Aging"},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-018-22610-4","article-title":"Cost-effective generation of precise label-free quantitative proteomes in high-throughput by microLC and data-independent acquisition","volume":"8","author":"Vowinckel J","year":"2018","unstructured":"Vowinckel J, Zelezniak A, Bruderer R, M\u00fclleder M, Reiter L, Ralser M. Cost-effective generation of precise label-free quantitative proteomes in high-throughput by microLC and data-independent acquisition. Sci Rep. 2018;8(1). doi:10.1038\/S41598-018-22610-4","journal-title":"Sci Rep"},{"issue":"11","key":"ref26","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1021\/ACS.JPROTEOME.5B00826","article-title":"Advancing Urinary Protein Biomarker Discovery by Data-Independent Acquisition on a Quadrupole-Orbitrap Mass Spectrometer","volume":"14","author":"Muntel J","year":"2015","unstructured":"Muntel J, Xuan Y, Berger ST, et al. Advancing Urinary Protein Biomarker Discovery by Data-Independent Acquisition on a Quadrupole-Orbitrap Mass Spectrometer. J Proteome Res. 2015;14(11):4752\u20134762. doi:10.1021\/ACS.JPROTEOME.5B00826","journal-title":"J Proteome Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/S12014-020-09283-W","author":"Macklin A","year":"2020","unstructured":"Macklin A, Khan S, Kislinger T. Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clinical Proteomics 2020 17:1. 2020;17(1):1\u201325. doi:10.1186\/S12014-020-09283-W"},{"issue":"3","key":"ref28","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1021\/ACS.JPROTEOME.8B00898\/SUPPL_FILE\/PR8B00898_SI_012.XLSX","article-title":"Comparison of Protein Quantification in a Complex Background by DIA and TMT Workflows with Fixed Instrument Time","volume":"18","author":"Muntel J","year":"2019","unstructured":"Muntel J, Kirkpatrick J, Bruderer R, et al. Comparison of Protein Quantification in a Complex Background by DIA and TMT Workflows with Fixed Instrument Time. J Proteome Res. 2019;18(3):1340\u20131351. doi:10.1021\/ACS.JPROTEOME.8B00898\/SUPPL_FILE\/PR8B00898_SI_012.XLSX","journal-title":"J Proteome Res"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1039\/D0MO00072H","article-title":"Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology","volume":"17","author":"Krasny L","year":"2021","unstructured":"Krasny L, Huang PH. Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. Mol Omics. 2021;17(1):29\u201342. doi:10.1039\/D0MO00072H","journal-title":"Mol Omics"},{"issue":"1","key":"ref30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/BIOSTATISTICS\/KXJ037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Johnson WE","year":"2007","unstructured":"Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118\u2013127. doi:10.1093\/BIOSTATISTICS\/KXJ037","journal-title":"Biostatistics"},{"issue":"D1","key":"ref31","doi-asserted-by":"publisher","first-page":"D607-D613","DOI":"10.1093\/NAR\/GKY1131","article-title":"STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk D","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D613. doi:10.1093\/NAR\/GKY1131","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13195-019-0512-1\/FIGURES\/3","article-title":"FDG-PET as an independent biomarker for Alzheimer\u2019s biological diagnosis: A longitudinal study","volume":"11","author":"Ou YN","year":"2019","unstructured":"Ou YN, Xu W, Li JQ, et al. FDG-PET as an independent biomarker for Alzheimer\u2019s biological diagnosis: A longitudinal study. Alzheimers Res Ther. 2019;11(1):1\u201311. doi:10.1186\/S13195-019-0512-1\/FIGURES\/3","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"ref33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/J.JALZ.2018.07.222","article-title":"Vascular dysfunction\u2014The disregarded partner of Alzheimer\u2019s disease","volume":"15","author":"Sweeney MD","year":"2019","unstructured":"Sweeney MD, Montagne A, Sagare AP, et al. Vascular dysfunction\u2014The disregarded partner of Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2019;15(1):158\u2013167. doi:10.1016\/J.JALZ.2018.07.222","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/NN.4492","author":"Zimmer ER","year":"2017","unstructured":"Zimmer ER, Parent MJ, Souza DG, et al. [18F]FDG PET signal is driven by astroglial glutamate transport. Nature Neuroscience 2017 20:3. 2017;20(3):393\u2013395. doi:10.1038\/NN.4492"},{"issue":"1","key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-021-85129-1","article-title":"BASP1 labels neural stem cells in the neurogenic niches of mammalian brain","volume":"11","author":"Manganas LN","year":"2021","unstructured":"Manganas LN, Dur\u00e1 I, Osenberg S, et al. BASP1 labels neural stem cells in the neurogenic niches of mammalian brain. Sci Rep. 2021;11(1). doi:10.1038\/S41598-021-85129-1","journal-title":"Sci Rep"},{"issue":"2","key":"ref36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0168-0102(94)90146-5","article-title":"Neuronal protein GAP-43 is a member of novel group of brain acid-soluble proteins (BASPs)","volume":"19","author":"Mosevitsky MI","year":"1994","unstructured":"Mosevitsky MI, Novitskaya VA, Plekhanov AY, Skladchikova GY. Neuronal protein GAP-43 is a member of novel group of brain acid-soluble proteins (BASPs). Neurosci Res. 1994;19(2):223\u2013228. doi:10.1016\/0168-0102(94)90146-5","journal-title":"Neurosci Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3389\/FMOLB.2021.719678\/BIBTEX","article-title":"Multifunctional Fructose 1,6-Bisphosphate Aldolase as a Therapeutic Target","volume":"8","author":"Pirovich DB","year":"2021","unstructured":"Pirovich DB, Da\u2019dara AA, Skelly PJ. Multifunctional Fructose 1,6-Bisphosphate Aldolase as a Therapeutic Target. Front Mol Biosci. 2021;8:788. doi:10.3389\/FMOLB.2021.719678\/BIBTEX","journal-title":"Front Mol Biosci"},{"issue":"5","key":"ref38","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.4049\/JIMMUNOL.175.5.3439","article-title":"Identification of Aldolase as a Target Antigen in Alzheimer\u2019s Disease","volume":"175","author":"Mor F","year":"2005","unstructured":"Mor F, Izak M, Cohen IR. Identification of Aldolase as a Target Antigen in Alzheimer\u2019s Disease. The Journal of Immunology. 2005;175(5):3439\u20133445. doi:10.4049\/JIMMUNOL.175.5.3439","journal-title":"The Journal of Immunology"},{"issue":"5","key":"ref39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7555\/JBR.30.20150131","article-title":"Autoantibodies in Alzheimer\u2019s disease: potential biomarkers, pathogenic roles, and therapeutic implications","volume":"30","author":"Wu J","year":"2016","unstructured":"Wu J, Li L. Autoantibodies in Alzheimer\u2019s disease: potential biomarkers, pathogenic roles, and therapeutic implications. J Biomed Res. 2016;30(5):361. doi:10.7555\/JBR.30.20150131","journal-title":"J Biomed Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/FONC.2020.00159\/BIBTEX","article-title":"Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis","volume":"10","author":"Zahra K","year":"2020","unstructured":"Zahra K, Dey T, Ashish, Mishra SP, Pandey U. Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis. Front Oncol. 2020;10:159. doi:10.3389\/FONC.2020.00159\/BIBTEX","journal-title":"Front Oncol"},{"issue":"JAN","key":"ref41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/FPHYS.2014.00522","article-title":"Alzheimer\u2019s disease: the amyloid hypothesis and the Inverse Warburg effect","volume":"5","author":"Demetrius LA","year":"2014","unstructured":"Demetrius LA, Magistretti PJ, Pellerin L. Alzheimer\u2019s disease: the amyloid hypothesis and the Inverse Warburg effect. Front Physiol. 2014;5(JAN):14. doi:10.3389\/FPHYS.2014.00522","journal-title":"Front Physiol"},{"issue":"3","key":"ref42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/S10522-017-9692-X","article-title":"A disease with a sweet tooth: exploring the Warburg effect in Alzheimer\u2019s disease","volume":"18","author":"Atlante A","year":"2017","unstructured":"Atlante A, de Bari L, Bobba A, Amadoro G. A disease with a sweet tooth: exploring the Warburg effect in Alzheimer\u2019s disease. Biogerontology. 2017;18(3):301\u2013319. doi:10.1007\/S10522-017-9692-X","journal-title":"Biogerontology"},{"issue":"9","key":"ref43","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/J.CMET.2022.07.014","article-title":"Warburg-like metabolic transformation underlies neuronal degeneration in sporadic Alzheimer\u2019s disease","volume":"34","author":"Traxler L","year":"2022","unstructured":"Traxler L, Herdy JR, Stefanoni D, et al. Warburg-like metabolic transformation underlies neuronal degeneration in sporadic Alzheimer\u2019s disease. Cell Metab. 2022;34(9):1248\u20131263.e6. doi:10.1016\/J.CMET.2022.07.014","journal-title":"Cell Metab"},{"issue":"10","key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELREP.2021.110102","article-title":"Aberrant role of pyruvate kinase M2 in the regulation of gamma-secretase and memory deficits in Alzheimer\u2019s disease","volume":"37","author":"Han J","year":"2021","unstructured":"Han J, Hyun J, Park J, et al. Aberrant role of pyruvate kinase M2 in the regulation of gamma-secretase and memory deficits in Alzheimer\u2019s disease. Cell Rep. 2021;37(10). doi:10.1016\/J.CELREP.2021.110102","journal-title":"Cell Rep"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-70850-0","author":"Liu Q","year":"2020","unstructured":"Liu Q, Walker D, Uppal K, et al. Addressing the batch effect issue for LC\/MS metabolomics data in data preprocessing. Scientific Reports 2020 10:1. 2020;10(1):1\u201313. doi:10.1038\/S41598-020-70850-0"},{"issue":"7","key":"ref46","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1021\/ACS.ANALCHEM.9B05460\/ASSET","article-title":"NormAE: Deep Adversarial Learning Model to Remove Batch Effects in Liquid Chromatography Mass Spectrometry-Based Metabolomics Data","volume":"92","author":"Rong Z","year":"2020","unstructured":"Rong Z, Tan Q, Cao L, et al. NormAE: Deep Adversarial Learning Model to Remove Batch Effects in Liquid Chromatography Mass Spectrometry-Based Metabolomics Data. Anal Chem. 2020;92(7):5082\u20135090. doi:10.1021\/ACS.ANALCHEM.9B05460\/ASSET\/IMAGES\/LARGE\/AC9B05460_0003.JPEG","journal-title":"Anal Chem"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1021\/JASMS.2C00341\/SUPPL_FILE\/JS2C00341_SI_002.PDF","article-title":"Cerebrospinal Fluid and Brain Proteoforms of the Granin Neuropeptide Family in Alzheimer\u2019s Disease","author":"Quinn JP","year":"2022","unstructured":"Quinn JP, Ethier EC, Novielli A, et al. Cerebrospinal Fluid and Brain Proteoforms of the Granin Neuropeptide Family in Alzheimer\u2019s Disease. J Am Soc Mass Spectrom. Published online 2022. doi:10.1021\/JASMS.2C00341\/SUPPL_FILE\/JS2C00341_SI_002.PDF","journal-title":"J Am Soc Mass Spectrom. Published online"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/J.MCPRO.2021.100076","article-title":"Spectral Prediction Features as a Solution for the Search Space Size Problem in Proteogenomics","volume":"20","author":"Verbruggen S","year":"2021","unstructured":"Verbruggen S, Gessulat S, Gabriels R, et al. Spectral Prediction Features as a Solution for the Search Space Size Problem in Proteogenomics. Mol Cell Proteomics. 2021;20:100076. doi:10.1016\/J.MCPRO.2021.100076","journal-title":"Mol Cell Proteomics"},{"issue":"12","key":"ref49","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1021\/PR200913A","article-title":"Analysis of the resolution limitations of peptide identification algorithms","volume":"10","author":"Colaert N","year":"2011","unstructured":"Colaert N, Degroeve S, Helsens K, Martens L. Analysis of the resolution limitations of peptide identification algorithms. J Proteome Res. 2011;10(12):5555\u20135561. doi:10.1021\/PR200913A","journal-title":"J Proteome Res"},{"issue":"4","key":"ref50","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3233\/JAD-170261","article-title":"A Systematic Review of Longitudinal Studies Which Measure Alzheimer\u2019s Disease Biomarkers","volume":"59","author":"Lawrence E","year":"2017","unstructured":"Lawrence E, Vegvari C, Ower A, Hadjichrysanthou C, De Wolf F, Anderson RM. A Systematic Review of Longitudinal Studies Which Measure Alzheimer\u2019s Disease Biomarkers. Journal of Alzheimer\u2019s Disease. 2017;59(4):1359. doi:10.3233\/JAD-170261","journal-title":"Journal of Alzheimer\u2019s Disease"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3073597\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3073597\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T17:14:40Z","timestamp":1689354880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3073597\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":50,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3073597\/v1","relation":{},"subject":[],"published":{"date-parts":[[2023,6,27]]},"subtype":"preprint"}}